



*Innovative back microsurgery*

**Press release**

## **Acquisition of an innovative system for mixing and injecting orthopaedic cement**

*An innovative solution to establish Vexim on the vertebroplasty market*

**Toulouse, February 28<sup>th</sup> 2013** - Vexim (FR0011072602 - ALVXM), a medical device company specialising in minimally-invasive treatment of vertebral fractures, today announced the acquisition of an innovative technological system in the injection of orthopaedic cement for its development in vertebroplasty.

### Major acquisition in vertebroplasty

Thanks to its SpineJack® implant, Vexim already had revolutionary technology for the mini-invasive treatment of vertebral compression fractures, notably enabling the anatomic restoration of fractured vertebra and the reestablishment of the spinal column's balance.

Thanks to the acquisition of a brand new system for mixing and injecting orthopaedic cement that complements the Company's SpineJack® technology, Vexim is expanding its presence in the field of vertebroplasty, which currently represents around half of mini-invasive procedures in the treatment of vertebral compression. This new system will thus allow surgery to be performed on indications where priority is given to stabilising the fracture and eliminating pain by injecting cement into the vertebra.

This innovation, patented and acquired in the form of an exclusive worldwide licence, will provide real benefits for physicians and patients alike thanks to its unique competitive advantages:

- compatibility with the use of ultra-high-viscosity cement, thus limiting the risk of leakage and allowing controlled cement distribution in the vertebra;
- precision injection: control and immediate stop of the injection;
- safe and secure technique: the physician has better control when carrying out the injection whilst maximizing the radiation safety distance;
- user friendly: an injection system with increased strength that can be manipulated with one hand.

## Launch in Europe and the United States in 2014

Simultaneously to its European launch in 2014, Vexim is considering introducing this unique system in the US market, which represents 60% of the vertebroplasty market by value<sup>1</sup>. This innovative system thus provides a real opportunity to access one of the world's largest markets.

## A comprehensive and innovative range on a high-potential market

Thanks to this positioning on the vertebroplasty segment and its exclusive vertebral restoration solution using the SpineJack®, Vexim will have a comprehensive offer in the innovative treatment of vertebral fractures, a dynamic market that is expected to see double-digit growth over the coming years. This trend is backed by socio-demographic factors associated with an aging population, increasing awareness by health professionals and better healthcare cover.

Vexim intends to meet these growing needs by pursuing its innovation and marketing efforts in relation to its avant-garde solutions, the aim being to eventually become the European leader in innovative back microsurgery.

Vincent Gardès, CEO of Vexim, comments: *“At the time of our IPO almost a year ago, as a young innovative company in the minimally-invasive spine surgery area, we pledged to become even more innovative every year in order to continually strengthen our competitive advantage. Thanks to this new solution in the field of vertebroplasty, we are proving that innovation is the driving force behind our development and the cornerstone of our continued growth.”*

### **Next press release:**

**2012 annual results: March 19<sup>th</sup> 2013\***

\*(date subject to modification)

### **About Vexim, the innovative back microsurgery specialist**

Based in Balma, near Toulouse (France), Vexim is a medical device specialist created in February. The Company has specialised in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital<sup>2</sup> and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a deformed or fractured vertebra and correcting the anatomy of the spinal column. The Company currently has 40 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors in Turkey, Argentina, India, Mexico, Brazil and United Arab Emirates. Vexim has been listed on NYSE Alternext Paris since 3 May 2012. For further information, please go to [www.vexim.com](http://www.vexim.com)

### **SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures**

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out in a mini-invasive manner, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack® technology benefits from the support of international scientific experts in the field of spinal columns, good medical-expense reimbursement systems in Europe and worldwide patent protection through to 2029.

---

<sup>1</sup> Source: Millennium Research Group 2012 data

<sup>2</sup> Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550M via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit [www.truffle.com](http://www.truffle.com) and [www.fcpi.fr](http://www.fcpi.fr).

## **CONTACTS**

### **Vexim**

**Vincent Gardès**

CEO

Tel: +33 5 61 48 48 38

[v.gardes@vexim.fr](mailto:v.gardes@vexim.fr)

### **NewCap.**

Financial Communications  
and Investor Relations

**Dusan Oresansky /**

**Emmanuel Huynh**

Tel: +33 1 44 71 94 92

[vexim@newcap.fr](mailto:vexim@newcap.fr)

### **Alize RP**

Press Relations

**Caroline Carmagnol**

[caroline@alizerp.com](mailto:caroline@alizerp.com)

Tel: +33 6 64 18 99 59

**Christian Berg**

[christian@alizerp.com](mailto:christian@alizerp.com)

Tel: +33 1 42 68 86 41



- **Name:** Vexim
- **ISIN Code:** FR0011072602
- **Ticker:** ALVXM

### **Disclaimer**

This press release and the information contained herein does not constitute or form part of, and should not be constituted as, an offer or invitation to sell or subscribe for, or a solicitation of any offer or invitation to acquire, dispose of or subscribe for, shares in Vexim ("the Company") in any country. The publication of this press release in certain countries may violate applicable regulations. With respect to the member states of the European Economic Area which have implemented the Directive 2003/71/EC of the European Parliament and the Council of November 4<sup>th</sup> 2003 (the "Prospectus Directive"), other than France, no action has been undertaken or will be undertaken to make an offer to the public of the Vexim securities requiring a publication of a prospectus in any relevant member state (other than France). As a result, the securities may not and will not be offered in any relevant member state (other than France) except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member state, or under any other circumstances which do not require the publication by Vexim of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member state. The information contained therein does not constitute an offer for securities in the United States, Canada, Australia or Japan or in any other jurisdiction. This press release should not be published, transmitted or distributed, directly or indirectly, into the United States, Canada, Australia or Japan. This press release is not an offer for sale or a solicitation of offers to purchase VEXIM securities in the United States. The securities of VEXIM may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. VEXIM does not intend to register any portion of an offering in the United States or to conduct a public offering of securities in the United States. This press release does not constitute an invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000 and is for distribution only to persons who (A) are outside the United Kingdom, or (B) are qualified investors as described in section 86(7) of the Financial Services and Markets Act 2000 (being persons falling within Article 2.1(e)(i), (ii) or (iii) of Directive 2003/71/EC) and (i) have professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order, or (iii) to whom it may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons. This press release contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Base registered with the Autorité des Marchés Financiers under number I.12-007 on March 28<sup>th</sup> 2012, and the Note d'Opération that was approved by the Autorité des Marchés Financiers under number 12-152 on April 5<sup>th</sup> 2012, changes in economic conditions, the financial markets or the markets in which VEXIM operates.